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Abstract
Background. The Nordic Cancer Registries are among the oldest population-based registries in
the world, with more than 60 years of complete coverage of what is now a combined population
of 26 million. However, despite being the source of a substantial number of studies, there is no
published paper comparing the different registries. We therefore conducted a systematic review
to identify similarities and dissimilarities of the Nordic Cancer Registries which could possibly
explain some of the differences in cancer incidence rates across these countries.
Method. We here describe and compare the core characteristics of each of the Nordic Cancer
Registries: (i) data sources; (ii) registered disease entities and deviations from IARC multiple
cancer coding rules; (iii) variables and related coding systems. Major changes over time are
described and discussed.
Results. All Nordic Cancer Registries represent a high quality standard in terms of completeness
and accuracy of the registered data.
Conclusions. Even though the information in the Nordic Cancer Registries in general can be
considered more similar than any other collection of data from five different countries, there are
numerous differences in registration routines, classification systems and inclusion of some
tumours. These differences are important to be aware of when comparing time trends in the
Nordic countries.
Nordic Cancer Registries – similarities and differences Version 23 August 2017
Only for your personal use until the paper will come out in Acta Oncologica.
3 3
Introduction
The cancer registries in the Nordic countries, Denmark, Finland, Iceland, Norway and Sweden
operate in similar demographic settings. The Nordic cancer registries are all based on total
populations, each having its unique personal identity code (PIC) system. The total population of
these five countries now exceeds 26 million, and more than 100,000 new cancer cases are
registered every year.
Notification of cancer is mandatory in all Nordic countries, and a high degree of comparability
and validity has been documented in the practices of the registries. Similar issues were addressed
in a 16-page questionnaire survey conducted in 2000 by the Association of the Nordic Cancer
Registries (ANCR) and the Danish Cancer Society. The results were published in a 262-page
document [1]. Close to 100% completeness of incident solid malignancies have been reported in
each of the registries [2-8]. Data from each of the five Nordic registries have been presented in
Cancer Incidence in Five Continents (CI5) – a compendium of cancer incidence data from
registries evaluated to have high quality data – from Volume I, covering the years 1958-1962 [9],
through to Volume X, covering the years 2003-2007 [10].
A history of close contact between the Nordic cancer registries has ensured many similarities
with data often being used for the purpose of comparative and multicentre Nordic studies.
Despite the similarities, a number of differences in cancer registration practices exists, but these
are rarely discussed when rates are compared. These differences will in particular affect studies
that compare the relative survival of cancer patients. Comparability issues could also explain
some of the observed temporal trends in cancer incidence, and projections of future cancer
burden.
The aim of this article is to describe the cancer registration systems in the Nordic countries in a
systematic fashion, and provide documentation on the similarities and dissimilarities of the
Nordic cancer registries. We also explain why the numbers of cancer cases published in national
cancer statistics are not always identical with those published in NORDCAN (ancr.nu), the joint
Nordic cancer statistics database [11,12].
Materials and Methods
For this paper, characteristics of the Nordic cancer registries were systematically described by
experts from each of the five Nordic cancer registries on the following aspects.1) Data sources of the cancer registry;
2) Registered disease entities (including precancerous lesions etc.); coding rules and deviations
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from them, such as multiple cancer coding rules by the International Agency for Research on
Cancer (IARC) and the International Association of the Cancer Registries (IACR); 
3) Variables available in the permanent cancer registry database or easily available from other
data sources via record linkage; coding nomenclatures related to these variables.
A set of questions was drafted by the first author (EP) and finalised in collaboration of all
authors. The answers were filled in a template by best national experts of registration procedures
and coding practices and synthesised in discussions between the fists author (EP) via email
discussions and in face-to-face meetings.
This paper describes cancer registration practices as of April 2017, with documentation of major
changes in the history of the cancer registration in each country. Examples are illustrated as
graphs produced with NORDCAN graphical tools (ancr.nu).
The numbers of cases registered were calculated by each Nordic cancer registry for the period
2009-2013 and then compared with the respective numbers shown in NORDCAN version 7.3
released in July 2016 [11]. All Figures in this paper except Figure 9 are made with the
NORDCAN graphical tool.
Results
All Nordic cancer registries are nationwide and population-based and have a long history. The
Danish Cancer Registry is the oldest, founded in 1942. The Cancer Registries in Finland and
Norway were founded in 1952, Iceland in 1954, and Sweden in 1958 (Table 1). We do not
describe cancer registries of the Faroe Islands and Greenland in detail, although data from these
regions are now accessible via NORDCAN. The Cancer Registry in the Faroe Islands was
functional during some periods since the 1960s and was re-established in 1994 [13]. Cancer data
from Greenland were coded and stored by the Danish Cancer Registry from 1943 until 2013. In
2014 Greenland took over the coding responsibility.
The completeness of data on incident cancers is considered to be very high already from the
founding of the Cancer Registry in each of the Nordic countries (Table 1). For Sweden, however,
data from the very first years are often not shown in the tabulations, e.g., the time trends in
NORDCAN start from year 1960 [11]. The Finnish Cancer Registry also includes information on
cases diagnosed in 1930-1952 in individuals who died from cancer or developed a new primary
cancer after 1 January 1953. The Icelandic Cancer Registry also includes countrywide
information on breast cancers diagnosed in 1911-1954, comprehensive data that were collected
for a doctoral thesis [14]. The completeness of the information for such early years is not known.
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Notifications of cancer are centrally handled in all Nordic countries except Sweden, where six
regional registries collect the notifications and perform checks before data are sent to the office of
the National Cancer Registry at the National Board of Health and Welfare.
Table 1 and Web Table 1 list administrative information, such as contact addresses, links to
instructions on data requests and permissions for access of data. Additionally, values for
commonly used indicators for cancer registry quality, proportion of death certificate only (DCO)
cases, and microscopically verified cases in 2009-2013 (range 93% to 98%) are presented in
Table 1. In Web tables, we also provide links to more complete documents on data quality.
Data sources
Information on cancer stems from multiple sources, including hospitals, institutions with hospital
beds, primary care physicians, pathology and cytology laboratories, and death certificates.
Additional data items for cancer cases already known to the Cancer Registry may be obtained by
record linkage with administrative health/disease registries (e.g. pathology registries, inpatient
hospital registries, cause-of-death registry).
In all Nordic countries, cancer notifications have been received from public hospitals from the
outset (Table 2). In Iceland, clinicians in private practice report only prostate cancers, while in
the other countries they report all malignancies. Cancer notifications from dentists are received
only in Denmark and Finland. This should not create incomparability in the cancer statistics,
because dentists are supposed to refer people with suspicious lesions to hospitals.
Currently, all countries receive notifications from pathology laboratories/departments. Since
2004, the information in the Danish Cancer Registry has been based on data retrieved by record
linkage to the National Patient Register, the National Register for Pathology, and the National
Cause of Death Register, supplemented with notifications from general practice [15].
Sweden is the only Nordic country with no legal basis to routinely use cancer information from
the death certificate notifications (DCN) to supplement the national cancer registry. This
information is important, as it adds primarily cases with poor prognosis following trace back of
DCNs to validate the diagnosis and retrieve information on date of diagnosis. Once identified and
verified from another source, these cases become death certificate initiated (DCI).
Non-inclusion of information from death certificate sources in Sweden reduces the completeness
of registration, particularly for poorly investigated cases without histology, which if included
would lower the proportion of morphologically verified cases (MV), which is 98% in Sweden. A
very high MV% – higher than might reasonably be expected – suggests over-reliance on
pathology laboratories as the source of diagnosis and deficiencies in case-finding from other
source.
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Due to the missing death certificate source, incident cases are incompletely registered in Sweden.
The number of missing cases was estimated at 4% of all cases in 1978 [2]. According to the
national cancer statistics of Sweden, there were more than 2600 death certificates stating cancer
as cause of death in 2014 with no corresponding records in the cancer registry; if 2000 of those
were verifiable and thus registrable cancers, this would mean about a 4% addition to the number
of new cancers ([16], pages 122-3). Hence, the proportion of missing cancer cases in the Swedish
Cancer Registry seems to be stable over calendar time, and it is also similar to the proportion of
DCI cancers in Iceland (4.4%) [7]. When comparing with data from the Swedish Cause of Death
Register and Patient Register, the largest underreporting to the Swedish Cancer Registry is
observed for cancers commonly diagnosed in advanced stages, such as cancers of the pancreas,
gallbladder, lung, oesophagus or liver, while the effect on the completeness of breast cancer
registrations, for example, is small. A research project to assess the impact on cancer incidence
and survival because of the non-inclusion of DCI cases in the Swedish Cancer Registry is
ongoing. Preliminary results based on record linkage to the Swedish Patient Register to validate
DCNs and retrieve a date of diagnosis suggest that age adjusted 1-year relative survival may be
overestimated by 2-3 percentage points for lung cancer, a malignancy often diagnosed at
advanced stage, while the effect on breast cancer survival was negligible.
In 1978, the under-registration in Sweden for leukaemia was as high as 18% [2], but may be
smaller now (see trend slopes in Figure 1). A large proportion of of the malignancies detected in
the Cause of Death Register only - and not registered in the Cancer Register - has not been
diagnosed or treated in hospital. This proportion is likely to be particularly high in the elderly
with malignancies with a poor prognosis, such as pancreatic cancer. However, similar patterns (a
declining incidence in the oldest age groups) are also clearly evident in the other Nordic countries
most likely reflecting factors related to diagnostic activity in non-hospitalised persons (Figure 2).
Cancers registered
The lists of disease entities registered by the Nordic Cancer Registries are so similar in all
countries that the total cancer incidence summed in the “All sites” category in NORDCAN can be
considered directly comparable between the countries (Table 3). Only three exceptions violating
the comparability are worth noticing (www.ancr.nu front page, link The NORDCAN database):
(i) Basal cell carcinomas are not registered in all cancer registries, or the registration may be
incomplete. Thus, both NORDCAN and national cancer statistics follow the tradition of
excluding basal cell carcinomas from their statistics on “all sites”. Before 1978, data from
Denmark do not separate basal cell and other skin cancers (Figure 3).
(ii) The incidence of urothelial tumours is not comparable over time between the Nordic
countries due to varying coding practices (Figure 4). From the early days of cancer
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registration in Denmark, it was decided to include urothelial tumours from grade 1-4,
unknown grade and “papilloma” in the bladder in the incidence figures because all of
them would develop into invasive cancers if not treated. In the 1980s an attempt was
made to record change in grade, but realising that changes occurred from high grades to
low grades and vice versa in the same patient, demonstrating the random variation based
on the biopsies taken, it was decided to keep the coding unchanged. Even if part of the
high incidence in Denmark is explained by differing coding practices, it is of note that
mortality rates for bladder cancer in Denmark are also higher than in the other Nordic
countries.
(iii) In NORDCAN, pituitary gland tumours are included in the category of brain and central
nervous system (even if they are tumours of the endocrine system). These tumours
include benign tumours and make up almost 10% of that category in all countries except
Finland, where only malignant cases are registered.
Factors such as changes in information sources and/or different diagnostic practices like cancer
screening will affect incidence. The steep increase in the incidence of prostate cancer after
introduction of the PSA screening test in the early 1990s (and in Denmark about 10 years later) is
a good example of this effect. In Denmark, another marked change in the incidence of prostate
cancer was observed from 2004, partly reflecting the inclusion of pathology register information
(Figure 5). Excessive testing with ultrasound that started in the 1990s created a spatio-temporal
cluster of thyroid cancer incidence around the city of Oulu in Finland (Figure 6).
Because of variations in the starting year, target ages, coverage and participation proportion, the
organised screening programs cause incomparability in trends for cervical, breast and colorectal
cancer between the Nordic countries. A countrywide organised cervical cancer screening
program started first in Finland and Iceland in the mid1960s and latest in Norway in 1995. The
effects can be seen in the trends of cervical cancer incidence (Figure 7). Organised nationwide
mammography screening among women aged 50-59 years (50-69 years since 2007) started first
in Finland in 1986 and latest in 2007-9 in Denmark (two counties in the 1990s, comprising 20%
of population), causing major increases in the incidence rates (Figure 8). In Denmark, invitation
to colorectal cancer screening for ages 50-74 years started in 2014, and increased incidence can
already be seen. Details of Nordic cancer screenings have been published elsewhere [17-19].
Multiple cancers in the same organ
Table 3 lists the number of cases included in the Nordic cancer registries, but not reported as
primary cancers in NORDCAN. The main reason for different numbers of invasive malignancies
between NORDCAN and each of the Nordic registries can be explained by national deviations
from the IARC/IACR multiple cancer coding rules [20]. NORDCAN strictly follows the
IARC/IACR rules and only counts the first malignancy in the organ or organ group and broad
Nordic Cancer Registries – similarities and differences Version 23 August 2017
Only for your personal use until the paper will come out in Acta Oncologica.
8 8
morphology category [20]. The national cancer registries, instead, do not follow the mechanistic
IARC/IACR rules, but evaluate if each cancer should be regarded as a new primary cancer. This
is reflected in differences between nationally published cancer statistics and NORDCAN.
The national coding rules differ between countries in how to count multiple tumours in the same
organ. This is especially the case for paired organs (lung, breast, kidney), but also for skin, colon,
and urinary tract system. E.g., in the Swedish cancer statistics, there were 20% more breast
cancer cases during the period 2009-2013 than in the NORDCAN statistics (Table 3). While
Iceland and Norway follow the IARC/IACR rules and only count the first breast cancer in their
official national reporting, there are about 8% additional cases of breast cancer diagnosed in
2009-2013 in their national cancer registry databases.
For colon and rectum cancer (ICD-O topographies C18-C20), Norway and Finland count each
tumour with a different two-digit topography or different morphology groups within a two-digit
topography as separate cancers. Denmark counts each tumour with a different ICD-O topography
code as a separate cancer. Some of the multiple tumour coding rules have changed over the years,
which further complicates this issue described in detail in the report of the earlier survey in 2000
([1], Table 5 in appendix 3).
The Swedish Cancer Registry includes all incident tumours, meaning that if several tumours are
detected at the same time, all tumours will be registered as separate entities regardless whether
they share the same morphology or not. Therefore, there are, e.g., much more multiple squamous
cell skin cancers in the Swedish Cancer Registry than in the other Nordic registries (Table 3).
Whether a tumour is a new disease entity, and thus reportable, or a recurrence of an earlier
diagnosed cancer is subject to the clinician’s evaluation in Sweden. The Swedish national
statistics report incidence of registered tumours but also give numbers of affected individuals for
major cancer forms.
Basal cell cancer
Basal cell carcinoma (BCC) of the skin has been registered with varying practices in the Nordic
countries (Figure 9). Due to its more benign nature, BCC is traditionally not included in the
official national cancer statistics and is not included in NORDCAN.
In Denmark, the coding used before 1978 does not make it possible to separate BCC from other
non-melanoma skin cancer. The new Danish registration system incorporated in 2004 has
doubled the BCC incidence, partly due to inclusion of cases only identified from the Pathology
Register. Only one BCC per person is registered. If a new registration is received, then the last
digit of the topography code of the first BCC is changed to indicate that this person has multiple
BCCs.
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The Cancer Registry of Norway started BCC registration in 1971, but there was a major drop in
registration during 1983-1992 followed by a period of stabile registration in 1993-2007. The first
BCC for each patient was registered as a separate entity, and all subsequent ones combined as a
“second BCC”, regardless of how many there were. The Cancer Registry of Norway still receives
pathology reports on BCC, but since 2008 no information about BCC has been registered in the
official national statistics, but is stored in a separate file from which it is possible to count the
number of persons having a BCC-report within a year. In Iceland, systematic registration of BCC
started in 1981, but it is not included in the national statistics. An average of about two BCC
cases has been registered per BCC patient.
From 2004, BCC cases in Sweden have been registered in a separate file. In the initial years of
registration, quite a large proportion of BCCs may have been erroneously counted as first BCCs,
since the actual first BCCs were diagnosed before 2004. The best estimate of current BCC
incidence rate seems to be about 100/100,000. The Finnish Cancer Registry has registered BCC
since 1953 but with varying coding rules. Currently, the first case is coded, and further
notifications are stored. The markedly lower rate in Finland compared to other Nordic countries
suggests that the Finnish Cancer Registry does not get information on all BCC cases.
Premalignant and borderline diseases
For a variety of purposes, Nordic cancer registries have collected information on premalignant
and borderline diagnoses that are not counted as actual cancers and therefore not included in the
official national cancer statistics.
Ovarian borderline tumours are registered in all Nordic countries but not included in the national
statistics. Historically, these practices have varied. In Denmark, borderline ovarian tumours have
been registered since 1978, but are not reported in routine statistics.
Registration of precancerous lesions of cervix uteri is common in the Nordic cancer registries,
because such information is needed for evaluation of the efficacy of screening programmes
aiming at the prevention of invasive cervical cancer. The terminology and list of reportable
lesions has, however, varied between the countries and over the years. In Finland, it was first
compulsory to report cervical squamous cell carcinoma in situ lesions (compulsory since 1961).
Registration of “dysplasia gravis” started around 1988, and “cervical intraepithelial neoplasia
(CIN) III” around 1991 (for more details, see Finnish Cancer Registry 2009, page 7). In Norway, the
current list of registered lesions includes, e.g., ASCUS, low- and high-grade squamous
intraepithelial lesions (LSIL, HSIL); for details, see [21]. The number of LSIL jumped from almost
zero before 2005 first to about 3,000 a year in 2005-2008, then to about 8,000 in 2009 and finally
gradually to almost 15,000 in 2015. Such jumps are related to added transfers of information from
the files of the screening program to the main database. In Denmark, there is a separate registry
for moderate and heavy dysplasia, dysplasia without specification, and cervical carcinoma in situ.
Reporting of light dysplasia has no longer been required after 1 January 2014. Cervical
Nordic Cancer Registries – similarities and differences Version 23 August 2017
Only for your personal use until the paper will come out in Acta Oncologica.
10 10
carcinomas in situ have been registered in the Swedish cancer registry since 1958, while HSIL,
which also include CIN II lesions of the cervix, are included since 2015.
In organs other than cervix, information on in situ tumours can be registered in the Nordic cancer
registries, and their numbers may be presented in official cancer statistics (Table 3). Finland, e.g.,
includes in situ carcinomas in all sites except for the skin, but the annual statistics only include
intraductal (i.e. in situ) carcinomas of the breasts as a separate non-cancer category and in situ
carcinoma of the urinary tract as part of invasive cases. Registration of skin melanoma in situ
started in Finland in 2015. In Denmark and Norway, in situ cancers of the urinary tract are also
registered and included in the national statistics. In situ cancers of the breast and some other sites
are registered in the Norwegian database, but not included in the national statistics. In situ
cancers of the skin and colon/rectum are no longer registered. In Iceland, in situ cancers of breast
and skin are registered, but not included in the national statistics. Sweden has registered
carcinoma in situ lesions in all anatomical sites from the beginning of cancer registration but not
reported them in their routine statistics for the years before 2013.Transition from a premalignant
lesion to invasive cancer (malignant) is registered differently in the Nordic countries. In Denmark
and Norway, the pre-invasive and invasive lesions will be registered as two separate entities if the
difference in dates of diagnoses is more than 4 months. An exception to this principle is the
registration of bladder cancer, where only the first tumour is registered even in a case when a
diagnosis of invasive tumour would be done after an in situ tumour. In Finland - the general
coding principle before 2017 was that if the time difference between the premalignant and
malignant lesion was shorter than one year, then only one cancer was registered with the
behaviour code of the invasive tumour and date of diagnosis of the premalignant one. Since 2017,
there is no time limit and the pre-invasive case is registered separately from the invasive one (if
diagnosed before the invasive cancer). In Iceland, this time limit is two months for skin cancer;
for other cancers it is evaluated individually for each case whether the premalignant and
malignant phase are considered as one event or two separate events. In Sweden, all phases of
cancer transition are registered as separate entities. The practice of sometimes using the date of
diagnosis of a premalignant tumour as the date of invasive tumour in the same organ causes a
slight immortal bias in the survival estimate.
Variables collected
The variables collected in the databases of the Nordic cancer registries are summarised in Tables
4-5. The electronic versions of the same tables (link to the table on ANCR pages) also provide
links to the nomenclatures used for coding these variables.
Data on patients
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In the Nordic countries, all residents are issued a unique personal identity code (PIC) at birth or
time of permanent residency. PICs were introduced in Sweden in 1947, Norway 1964, Iceland
1965, Finland 1967, and in Denmark in 1968. PICs are used for every contact in the health system
and also as key identifiers in each of the Nordic cancer registries. They thus represent a reliable
tool when linking information on individuals across registries, including follow-up for death or
emigration. Before introduction of PICs, the key identifiers for a person were name, sex and date
of birth. Now, information on sex and date of birth are included in the PIC (except for Iceland
where sex is not included), and the name is only needed if there is an error in the PIC reported to
the cancer registry.
Cancer registries are updated with dates of death from the population registration system and the
national cause-of-death registry at least once a year. Date of emigration is also important as an
end-of-follow-up information in numerous routine tabulations (incidence, prevalence, mortality,
survival), and it is directly available in all Nordic cancer registry databases except the Danish
one. Information on immigration can be received via record linkage to the national population
registries (Table 4).
The causes of death of patients are received from the national cause-of-death registries in all
Nordic cancer registries. The Swedish Cancer Registry only receives information on the
underlying cause of death, and the Icelandic Registry only on causes of death with cancer
diagnoses. Differently from the other cancer registries, the Finnish Cancer Registry re-evaluates
cancer deaths together with incidence data from the registry. This leads to some differences
between the official cause of death and the FCR mortality statistics, especially in entities with
common metastatic sites such as liver, lung or brain.
Data on residence have been available down to the level of municipality for all Nordic cancer
patients since 1971. The Swedish and Norwegian cancer registries can classify cases by even
smaller administrative regions, and in Finland, the map coordinates of residence can be linked to
cancer patients diagnosed in 1981 and later.
Data on ethnicity are not available in any of the Nordic cancer registries, but country of birth is
available in the Finnish, Icelandic and Swedish Cancer Registries. The numbers of foreign-born
inhabitants range from about 6% in Finland to more than 17% in Sweden, with an average of
11%. The vast majority of inhabitants in the Nordic countries are Nordic-born, but in recent
decades an increasing part of immigrants are from Eastern Europe, Asia and Africa. Data from
the cancer registries can be linked to data on immigration from the population registries, as was
recently done in Norway [22].
Collection of other demographic data such as occupation, educational level, language (mother
tongue), and number of children were attempted in the early years of cancer registration in the
Nordic countries, but the quality of the data was so poor that it was deemed not useful. If needed,
such data can be obtained from the national population registries or census data from the
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statistical bureaus, as was done e.g. in the Nordic Occupational Cancer (NOCCA) study [23] or
in the Danish CANULI project [24]. The Finnish Cancer Registry can now use the socio-
demographic data on education and occupation in routine statistics and internal research as
agreed in 2014 with Statistics Finland.
Data on cancers
Key variables needed for production of routine incidence statistics
Most of the routine statistics on cancer incidence can be estimated if information is available on
date of diagnosis, topography, morphology and behaviour (benign, in situ or invasive/malignant)
of the tumour. These variables are therefore the main focus of all Nordic cancer registries and
have always been collected and precisely coded. For some cancer types, the morphology code
adds essential information, but collection of that information has not occurred or been consistent
in all countries throughout the registries´ history. In Denmark, there were only certain broad
morphology categories for some primary sites coded in the cancer registry records of the earlier
years. Before 2004, notifications (except autopsies) in Denmark were not received directly from
the pathologists, but the morphological information was a transcript of the pathological report
provided by the clinician. From 2004 it has been included automatically.
All Nordic cancer registries currently provide ICD-O-3 codes for topography, behaviour and
morphology. The older cancer cases may, however, have been originally coded according to
earlier versions of the ICD and various nomenclatures for morphology, and then subsequently
bulk-translated using an algorithm to match old codes with the best-fitting current codes. To use
Finland as an example: until 2007, the morphology was coded according to a slightly modified
version of the old Manual of Tumor Nomenclature Coding (MOTNAC) [25] which only had 75
code values. These codes were converted in 2007 to the morphology codes of ICD-O-3 with
hundreds of alternative code values. This conversion could not be 100% precise. Therefore, detailed
assessment of the incidence of several specific morphologies can only be started from 2007. If
necessary, it is possible to re-code the old cases according to current nomenclature from the free-text
diagnoses of the pathology reports stored in the cancer registry database. Unexpected changes in
trends of incidence rates should therefore be checked against changes in classification systems.
With the introduction of ICD-O-3 in 2000, new entities of haematological malignancies were
added. Most substantial was the conversion of myeloproliferative diseases (for example
polycythaemia vera) and myelodysplastic syndromes to malignant from being of unknown
behaviour. The comparability of data on these malignancies is dependent on when the registration
of these new cancer entities started in each of the Nordic countries, and what is the coverage of
registrations in each country. For example, in Finland the coverage is notably lower than for solid
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cancers [26]. Thus, for earlier years especially, comparability of data on these entities between
countries is lower than for solid cancers.
Data useful for survival statistics – disease stage
Precise and comparable information on tumour stage is important, especially in Nordic comparisons
of survival of cancer patients. Unfortunately, not all countries have had access to complete data, and
the coding of disease stage has varied over time and between countries. Cancer registries of Norway
and Finland have from the beginning of cancer registration recorded a broad staging variable
(localised – regional – distant - unknown) that is quite similar in both countries. In recent years, all
Nordic cancer registries have been trying to improve the completeness and accuracy of TNM
information, but further improvement is needed. Still in the 2010s in Finland, information on some
part of TNM was only available for a maximum of 50% of newly diagnosed cancer patient
depending on the primary site. The NORDCAN group is now working on a project to look more
thoroughly at TNM for all Nordic cancer registries with a separate publication later on this work.
Information on metastases at diagnosis has been collected by the Icelandic Cancer Registry since
1995 for colorectal cancer, since 1998 for prostate cancer and since 2010 for breast cancer and skin
melanoma. This is done concomitantly with registration of the TNM stage, by special registrars who
search for the information in electronic patient records. None of the Nordic cancer registries has
collected complete information on later metastases cancer recurrence.
Data on cancer treatment – routine data and quality registries
With regard to treatment, the Norwegian and Finnish cancer registries have asked for information on
the first-line treatment given (or planned) for the first year after diagnosis. However, the
completeness of even such limited information is far from perfect, mainly because the treating units
– often several different units per patient ‒ are not highly motivated to report. Since 2017, the
Finnish Cancer Registry collects treatment data based on the Nordic Classification of Surgical
Procedures (NCSP) codes. Iceland has collected information on the treatment of prostate cancer
patients since 1999, while Denmark stopped collection of treatment information in 2004 (because it
is available from the Hospital Discharge Registry). The national Swedish Cancer Registry never
collected information on treatment. One possible way of retrieving treatment information would be
to search information from the national hospital registries. This source covers all cancer types, but
the information is generally restricted to date and code of surgery. More detailed information for
selected cancer types and restricted time periods may be obtained from diagnose specific quality
registers.
The Cancer Registry of Norway collects more detailed information on cancer treatment in nine
quality registries, the oldest one covering childhood cancer patients from 1985 onwards (Web Table
6). One main purpose of these registries is to provide data on whether cancer treatment is given
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according to national guidelines. Similar quality registries with extended data have been operating in
other countries but have not been controlled by the cancer registries.
In Sweden, more than 25 clinical cancer registries are in operation. Launched regionally on a
small scale in the early 1990s for the purpose of quality assessment of cancer care, these
databases now have national coverage and share a common platform (INCA – information
network for cancer) since 2008. Compared to the Swedish Cancer Registry, the resolution is
considerably higher with information available on diagnostics, tumour characteristics and
treatment with a completeness usually exceeding 95% compared to the mandatory reporting to
the cancer registry (Web Table 7). The clinical cancer registries are administered by the network
of Regional Cancer Centres and are extensively used for quality assessment and research.
In Denmark, 22 clinical cancer groups exist, most of them with quality registries (www.DMCG.dk).
The oldest one started in 1976 with the aim to ensure optimal diagnostic procedures and treatment
for breast cancer patients. The quality registers for breast and for lung cancer were used for
validating the new procedure for constructing the Danish Cancer Registry.
The Icelandic Cancer Registry has been the only institution in Iceland that has registered clinical
variables in a standardised way. A limited number of variables for cancers of the colon, rectum,
breast and cervix plus melanoma have been registered prospectively since 2010. However, the
University Hospital of Reykjavik is preparing to implement population-based quality registration
in co-operation with the ICR, similar to the Swedish INCA system.
In Finland, there are currently no clinical cancer registries with national coverage and systematic
information exchange with the Finnish Cancer Registry. National decisions as to what should be
collected are still missing but will be initiated with collaboration together with five regional
cancer centres starting their work in 2017.
Discussion
Data sources
The data sources in all Nordic cancer registries are similar, and therefore the cancer data are
overall comparable. In Sweden, however, information from death certificates has traditionally not
been used as an additional routine source for the cancer registry. At present, there are legal
obstacles to disseminate death certificate data as a basis for trace-back. Because of this, the
proportion of non-registered cancer cases in Sweden is about 4 percentage units higher than in the
other Nordic countries. The lack of DCI cases in Sweden has to be considered when comparing
cancer survival between Sweden and the other Nordic countries and also when assessing the data
quality by the M/I proportion. It also has some effect on incidence rates of cancer types that more
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often than others are identified from death certificates, such as chronic leukaemia or cancers of
the lung and pancreas in the elderly [7].
Another issue that may have an effect on comparability of data from different regions and
different time periods is the reporting activity. In Finland, e.g., the number of clinical cancer
notifications – the majority of which are still completed manually - has decreased during recent
years, which means that the completeness of cancer registration is more dependent on
information received from pathology laboratories and death certificates. Fortunately, reporting
from these two sources to the cancer registry is semi-automatic and not dependent on individual
persons sending notifications. The earlier practice in Finland was to send out questionnaires to
the treating hospitals identified from the laboratory notifications or death certificates if the
clinical notification was missing, but – due to the change in the entire reporting system since
2017 – this practice was discontinued for cancers diagnosed after 2012. Thus, the quality (e.g.
more DCO-cases) of the Finnish Cancer Registry data is temporally lower for the most recent
diagnostic years [8].
Registered disease entities
Registration of subsequent primary tumours in patients with one tumour has been an important
tool in numerous studies of shared risk factors of cancers (e.g., [27]) and late effects related to
treatment of the first malignancy (e.g., [28]). In special instances, it would be important to assess
the risk of second primary tumours in the same organ, e.g. in the study on risk of new breast
cancer among women who took hormonal therapy after their first breast cancer [29]. For such
cases, it is important that the Nordic cancer registries continue to register all malignancies of the
same organ groups. Because new primary cancers in same organs also require treatment
resources, they are counted as separate malignancies in national cancer statistics in Denmark,
Finland and Sweden. For international comparison, though, it is recommended to use numbers
calculated according to the IARC/IACR rules for reporting cancer incidence, because the national
rules for multiple cancer coding have varied over the several decades of cancer registration, and
they still vary between countries.
Registration of non-malignant disease entities has been useful in numerous studies. As an
example, borderline ovarian tumours have been studied as part of clustering of different cancer
types in same families [30], and precancerous lesions of cervical cancer have been an important
outcome in studies of the effects of cervical cancer screening or HPV vaccines [31-34]. For the
latter type of research, it would also be useful to have information on the low-grade lesions, but
for the time being only the Cancer Registry of Norway can offer such information for recent
years.
Registration of BCC of the skin has been controversial. According to the ICD-O coding system,
BCC should be counted as a malignant tumour with the behaviour code 3, but most cancer
registries in the world do not register it. In the Nordic countries, there have been different policies
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as to the registration of BCC, and therefore it is impossible to produce comparable time trends for
overall cancer incidence that would include BCC. The current policy in registration of BCC cases
is to collect data on BCC cases from electronic sources, but store them in a separate data base and
do much less extensive manual coding and quality assurance operations compared to the data in
the main cancer registry data base.
Registered variables
Completeness and accuracy are high for the key variables needed for production of standard
incidence statistics, i.e., for the main output of the cancer registries. The changes in ICD versions
do not cause such jumps in time series of cancer incidence in any Nordic countries that may be
seen in the official time series of cancer mortality.
However, there is also a demand for more extensive data details than those needed for basic
incidence tabulations. All Nordic cancer registries can provide data to external researchers for
epidemiological studies. In addition, the cancer registries in Finland, Iceland and Norway are
themselves active research institutes for epidemiological research; own active use of cancer data 
is considered an important tool in quality assurance [35]. Until 1997, the Danish Cancer Registry
was hosted by the Danish Cancer Society where researchers also actively used the registry for
research. After cancer registration was moved to the National Board of Health in 1997 (now the
National Danish Health Data Authority), the Danish Cancer Society Research Centre each year
receives a copy of the file for research purposes. In Sweden, many epidemiological research
projects originate from the Regional Cancer Centres where the initial recording of reported cases
takes place.
In more detailed studies of cancer, variables such as the morphologic type of the tumours,
markers, stage, and treatment are often useful, and there is ongoing activity to improve the
content of these in the Nordic cancer registries.
A joint vision in the Nordic countries is that the health care system should provide an efficient
and equitable health care service to all residents, irrespective of socioeconomic position, ethnicity,
and place of residence. Therefore, there are increasing demands to have such characteristics
available in the cancer registries. There is a long tradition of linking the cancer patient file with
census variables for research purposes (e.g., [23,24,36-38]). Such record linkages have required
separate permissions. Since 2014, the Finnish Cancer Registry has the right to obtain – as an
annual routine – population census data on occupation, education and socioeconomic position
from Statistics Finland for all cancer patients and use them in its routine tabulations (but not give
out for external research purposes). Therefore, it will be possible to produce routine incidence
statistics stratified by these factors and follow development in equity cancer incidence, survival
and mortality.
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Because of the increasing size of immigrant populations, it has become important to be able to
stratify cancer incidence statistics according to migrant status. For that reason, the variables
related to migration need to be easily accessible. Because the cancer patterns of some immigrant
populations are very different from those of the Nordic populations, the increasing proportion of
residents born abroad complicates the interpretation of time trends. Because the percentage of the
foreign-born also varies between countries – currently from 6% in Finland to 17% in Sweden – it
has an effect on the comparability of cancer incidence rates among the inborn populations
between the countries.
Data on residence have been available on the level of municipality for all Nordic cancer patients
since 1971. This has made it possible to produce statistics for smaller regions as well as small-
area-based maps (such as Figure 6; for graphical method see [39]) and map animations on cancer
incidence [40] and mortality [41]. Due to changes in municipal size and number, an alternative
system has been developed for creating small-area regions on the basis of map coordinates (e.g.,
[42,43]). This is especially useful in creating longer regional time series when the borders of
larger areas change over time.
Conclusion
The Nordic Cancer Registries are among the oldest population-based registries in the world, with
more than 60 years of complete coverage of what is now a combined population of 26 million.
The long history causes challenges in time series: the diagnostic methods, medical terminology,
and classification nomenclatures have changed over time. Still, all Nordic Cancer Registries
represent a high-quality standard in terms of completeness and accuracy of the registered data
throughout their existence. Even though the information in the Nordic Cancer Registries can be
considered more similar than any other collection of data from five different countries, there are
some details that need to be understood in comparative studies of specific cancer entities.
So when can NORDCAN data be used, and when does a researcher need to use national data?
For a more general overview of cancer trends in the Nordic countries, we think the differences
between the countries are so small and many of them are dealt with the IARC check rules that it
is clearly beneficial to start with NORDCAN data. To completely understand epidemiologic
trends of one cancer, the differences in registration, screening and coding pointed out here,
should be taken into account. For that purpose, we recommend that a researcher uses the national
statistics supplemented with  other national data (e.g. treatment details, spreading).
Recent international comparisons of cancer incidence and outcomes have highlighted the
potential impact of differences in registration practices, and the need to increase comparability
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between cancer registry operations [44,45]. This overview is part of our efforts to increase such
comparability between our registries.
This article describes the cancer registration systems in the Nordic countries – as they are in 2017
– in a systematic way that is believed to be useful when Nordic cancer studies are planned and
carried out. However, there are continuous developments in the cancer registration processes,
data contents and other issues. Therefore, the tables describing data sources, cancer entities
registered, code nomenclatures, variables collected and principles on how to get access to cancer
registry data (web Tables in this article) will be made available on the pages of the Association of
the Nordic Cancer Registries (ancr.nu) and updated whenever there are changes to these issues in
any of the Nordic cancer registries. The same tables will also be linked to the web pages of
NORDCAN and of the Nordic Cancer Registries. Vigilant work to keep up the comparability is
essential ‒ otherwise the quality will decline.
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Table 1. Nordic cancer registries, administrative facts and quality issues. For questions on how to contact the Cancer Registry; how to apply
information from the Cancer Registry (with links to forms and instructions); links to documents on data protection principles and to
publications on data quality; please see the more detailed web version of this table.




Cancer Society of Finland,
Finnish Cancer Registry ‒












Board of Health and
Welfare
Founded 1942 1952 1954 1952 1958
Earliest/first complete year of
cancer registration
1943/1943 1930/1953 1911/1955 1952/1953 1958
Percentage of death
certificate only (DCO) cases
(NORDCAN data 2009-2013)
0.3% 1.2% in 2009-2011 (tracing of
DCI data for 2012+ delayed)
0.3% 1.1% ‒
Percentage of microscopically
verified (MV) cases (NORDCAN
data 2009-2013)
95% 93% 95% 94% 98%
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Table 2. Data sources of the Nordic cancer registries (routine data collection).
Denmark Finland Iceland Norway Sweden

















Private clinicians Yes Yes Yes, only for prostate





Dentists Yes Yes No No No
Inpatient registry Yes No1 2000+ (automatic
reporting)
1998+ (in- and outpatients) No











Laboratories, haematological reports No Yes Yes (automatic reporting) No (only samples sent to
pathological laboratories)
Yes









from Statistics Iceland until
2009 and from Directorate
of Health 2010+)
Yes (automatic reporting,
data file and picture files of
death certificates)
No
Radiotherapy data (from all machines) No No No 1997+2 No
1 Since 2015 the hospital discharge data has been available for cross linkage with the Cancer Registry from year 1996 and can be used to complement
possibly missing cases and to confirm DCI-cases.
2 Data items: region being treated; diagnosis (ICD-10); intention of treatment; date for start of treatment; number of days for treatment; date for end of
treatment; total dose; total number of fractions.
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Table 3. Numbers of cancers and other disease entities collected by the Nordic cancer registries, 2009-2013.
1 The numbers in brackets indicate that these numbers are not shown in the national routine statistics publication.
Disease / disease group
Number of registered cases in 2009-2013
Denmark Finland Iceland Norway Sweden
1. NORDCAN cancer entities
(NORDCAN 7.3; Engholm et al. 2016) 186,141 150,441 7,360 146,007 272,658
Disease entities registered in the national registries but not included in
NORDCAN tabulations1
2. Cancers registered in the national registries, but not included in
NORDCAN
2.1 Multiple cancers in same organ group2 1,823 2,089 [147] [4,309] 24,714
2.1.1 Breast 555 1,261 [81] [1,240] 6,983
2.1.2 Skin, melanoma 0 106 0 [687] 1181
2.1.3 Skin, non-melanoma, excluding basal cell carcinoma 0 576 0 [165] 7,846
2.1.4 Colon 390 31 [21] [814] 1,728
2.1.5 Bladder etc. 749 91 [26] [423] 820
 2.2 Polycythaemia vera 678 376 [14] [349] 793
2.3 Skin, basal cell carcinoma 58,208 40,866 [1,671] [40,606] 208,985
2.4 Other excluded categories 2608 43 0 89
3. Premalignant or borderline diseases registered in the national registries
but not included in NORDCAN
3.1 Ovary, borderline cancer [880] 767 [39] [788]  810
3.2 Cervix uteri, precancerous lesions / in situ  26,835/2,648  5,872  [25] [60,674] 14,568 (CIN III)










3.4 Other 363 16
4. Other registrations 0 [636] [23] [305]
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2 See IARC/IACR multiple coding rules, organ grouping in multiple coding (http://www.iacr.com.fr/images/doc/MPrules_july2004.pdf)
Table 4. Variables on cancer patients registered by the Nordic cancer registries.








For persons resident 1 Dec
1965+
For persons resident 1964+ Yes
Date of birth Yes Yes Yes Yes Yes
Sex Yes Yes Yes Yes Yes
Municipality of residence 1968+ Yes Yes 1971+ Yes
Occupation Until 2003 Yes No No No
Education No Yes No No No
Socio-economic position No Yes No No No
Date of immigration No Yes No 2015+ Yes
Country of origin No No No No No
Country of birth No Yes Yes No Yes
Date of emigration Yes Yes No Yes Yes
Vital status Yes Yes Yes Yes Yes
Date of death Yes Yes Yes Yes Yes
Underlying cause of death No Yes Yes (only for those who die from cancer) Yes Yes
Other causes of death No Yes 2003+ (only if the cause is cancer) Yes No
Incidental Autopsy Yes Yes Yes Yes (only for medical autopsies) Yes
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Table 5. Variables related to each cancer registered by the Nordic cancer registries.
Yellow background: This information is not directly available (in a qualitatively accurate manner) but may be derived with a modest extra effort
Variable Denmark Finland Iceland Norway Sweden





Topography / primary site Yes as ICD-10 Yes Yes Yes Yes
Morphology / histology Yes Yes. Yes Yes Yes, with limitations
before 1993
Behaviour / malignancy Yes Yes Yes Yes Yes
Method of confirmation Yes Yes Yes Yes Yes
Stage at diagnosis Before 2004 Yes No Yes No
TNM 2004+ Incomplete 2010+ for selected sites 1993+ for selected sites;
incomplete
2004+
Later metastases, recurrences No No No No No
Treatment Before 2004 (2004+
available via linkage to
the Hospital Discharge
Registry)
Yes, not complete 1999+, only for prostate
cancer
Yes No
Symptoms No No No Until 2011, incomplete;












(died of this cancer; died
of other causes).
More detailed information
available from 9 quality
registries of the Cancer
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WEB TABLES.
Details that are now in footnotes will be hidden behind the links.
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Web Table 1. Nordic cancer registries, administrative facts and quality issues.



















Board of Health and
Welfare
Founded 1942 1952 1954 1952 1958
Earliest year of registered
cancer diagnosis
1943 1930 (previous
malignancies for persons with
cancer diagnosed 1953+;
diagnoses of patients died
from cancer 1953+)
1955 (breast cancer incidence
also for 1911-1954, based on
study by Snaedal 1965)
1952 1958
First year of incidence
registration considered
complete 1943 1953 1955 1953 1958







www.cancerregistry.fi www.krabbameinsskra.is www.kreftregisteret.no http://www.socialstyrelsen
.se/register/halsodataregi
ster/cancerregistret
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How to apply information
from the cancer registry
(with link to forms and
instructions)?
Contact the Researcher






























rules for confidentiality in Appendix 2
Information about data



















Storm et al. 1997 (link
to pdf received from Hans
Storm); Gjerstorff 2011
Teppo et al. 1994 (link to
pdf received from Acta Oncol);
Leinonen et al. 2017
(partly describing an
exceptional period)





















cases (NORDCAN data 2009-
2013)
0.3% 1.2% in 2009-2011





cases (NORDCAN data 2009-
2013)
95% 93% 95% 94% 98%
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Web Table 2. Data sources of the Nordic cancer registries (routine data collection).
Denmark Finland Iceland Norway Sweden















Yes (manual reporting, mostly
electronically)
Yes
Private clinicians Yes Yes Yes, only for prostate
cancer, manual reported
on paper
Yes (manual reporting, mostly
on paper)
Yes
Dentists Yes Yes No No No
Inpatient registry Yes No1 2000+ (automatic
reporting)















No Yes Yes (automatic
reporting)
No (only samples sent to
pathological laboratories)
Yes
Laboratories, cytological reports No Yes Yes (automatic
reporting)
Yes (automatic reporting, both
paper and electronically)
Yes





Iceland until 2009 and
from Directorate of
Health 2010+)
Yes (automatic reporting, data
file and picture files of death
certificates)
No
Radiotherapy data (from all
machines)
No No No 1997+2 No
1 Trial use 1985-1988: after validation process 965 cancers added. Since 2015 the hospital discharge data 1996+ have been available for cross linkage
with the Cancer Registry and can be used to complement possibly missing cases and to confirm DCI-cases.
2 Data items: region where treated; diagnosis (ICD-10); intention of treatment; date for start of treatment; number of days for treatment; date for end of
treatment; total dose; total number of fractions.
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Web Table 3. Numbers of cancers and other disease entities collected by the Nordic cancer registries, 2009-2013. The percentages in
Italics indicate the difference between the national routine statistics publications and NORDCAN.
Disease / disease group
Number of registered cases in 2009-2013
Denmark Finland Iceland Norway Sweden
1. NORDCAN cancer entities*
(NORDCAN 7.3; Engholm et al. 2016) 186,141 150,441 7,360 146,007 272,658
Additional cancers / disease entities registered but
not included in NORDCAN tabulations
2. Cancers registered in the national registries,
but not included in NORDCAN
2.1 Multiple cancers in same organ group** 1,823 2,089 [147] [4,309] 24,714
2.1.1 Breast








2.1.2 Skin, melanoma 0
(if there is a second skin melanoma,
the topography code of the first skin
melanoma is changed to C43.8
“multiple locations”)
106 (1.7%) 0
(only the first case
is registered)
[687] (8.3%) 1,181 (8.0%)
2.1.3 Skin, non-melanoma, excluding
basal cell carcinoma
0
(if there is a second non-melanoma
skin cancer, the topography code of
the first non-melanoma is changed to
C44.8 “multiple locations”)
576 (7.8%) 0
(only the first case
is registered)
[165] (2.2%) 7,846 (38.9%)
2.1.4 Colon 390 (2.8%) 31 (0.3%) [21] (4.2%) [814] (6.2%) 1,728 (8.8%)
2.1.5 Bladder etc.
(ICD-10: C65-68+D09.0-1+ D30.1-9+D41.1-9)
749 (7.6%) 91 (1.6%)
(includes in situ and
PUNLMP cases)
[26] (6.9%) [423] (6.2%) 820 (6.1%)
 2.2 Polycythaemia vera
(to be included in NORDCAN cancer entities in Fall 2017)
678 376 [14] [349] 793
2.3 Skin, basal cell carcinoma 58,208 40,866 [1,671]
[40,606]
(not stored in the actual
Cancer Registry data base) 208,985
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Disease / disease group
Number of registered cases in 2009-2013
Denmark Finland Iceland Norway Sweden
2.4 Other excluded categories Myelodysplastic syndrome:
1,264;
Other not specified tumours in
lymphatic and and
haematopoietic tissue: 1,344
(In NORDCAN edition in Fall 2017
there will be new categories for
these cancer entities. 43 0 89
3. Premalignant or borderline diseases registered
in the national registries but not included in
NORDCAN
3.1 Ovary, borderline cancer [880] 767 [39]
[788] +
[318 other premalignant
ovarian tumours]  810
3.2 Cervix uteri, precancerous lesions / in situ  26,835/2,648  5,872  [25] [60,674]
14,568 (CIN
III)













3.4 Mola and neoplasma placenta 363 16
4. Other registrations
4.1 Cancers of persons living abroad  0 [567]  [23] [305]  0
4.2 Preregistered possible cancers, waiting
for additional data to confirm the diagnosis
 0 [69]  0 0  0
* Taken from NORDCAN 7.3 (Engholm et al. 2016). National exceptions from strictly comparable joint Nordic registration principle: see http://www-
dep.iarc.fr/NORDCAN/english/frame.asp?o=database.
** See IARC/IACR multiple coding rules, organ grouping in multiple coding (http://www.iacr.com.fr/images/doc/MPrules_july2004.pdf)
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Web Table 4. Variables on cancer patients registered by the Nordic cancer registries.
Yellow background: This information is not directly available (in a qualitatively accurate manner) but may be derived from other sources with a
modest extra effort.




alive and living in DK from
1968 (checked with PR)
Available for persons














Only cancer cases for
persons registered in the
population register are
included. Notifications for
persons without a valid birth
number/ PIC are saved in a queue,
and checked against PR for a few
years before they are deleted if no
match can be found.
Yes (checked with
PR)
Date of birth Yes Yes Yes Yes Yes









the beginning of year
of cancer diagnosis
searched from PR). Plan
to use coordinate-based place







residence January 1st the
year of diagnosis,
incomplete before 1971).
Since 1990 also "grunnkrets"
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Variable Denmark Finland Iceland Norway Sweden
Occupation Available until 2003. Can be
retrieved from SO.
Yes (from SO for patients who
participated population census
1975 or later)
No No. Information was collected in
cancer notification but with
incomplete reporting, so
registration ended in 2011/2012.
Information on occupation can be
linked from Statistics Norway for
specific research projects after
research approval.
No
Education No. Can be retrieved from SO. Yes (from SO for patients who
participated population census
1975 or later)
No No. Information on education can
be linked from SN for specific
research projects after research
approval.
No (Received via record




No. Can be retrieved from SO. Yes (from SO for patients who
participated population census
1975 or later)
No No. Information on income can be
linked from SN for specific research
projects after research approval.
No (Received via record




No (available from PR if needed) Yes (from PR for patients not
died before 1967)
No Yes, from 2015 Yes
Country of origin No (available from PR if needed) No (available from PR if
urgently needed)
No No (could be obtained from
linkage with SO or PR, but there are
strict restrictions for access)
No
Country of birth No (available from PR if needed) Yes (from PR for patients not
died before 1967)
Yes No (could be obtained from
linkage with SO or the population
register, but there are strict





Yes Yes (from PR for patients not
died before 1967)
No Yes Yes
Vital status Yes (for each registered person it
is checked that he exists in the PR
alive, emigrated of died)
Yes (for each registered
person it is checked that he
exists in the PR alive,
emigrated of died)
Yes (for each
registered person it is
checked that he exists in
the PR alive or dead)
Yes. Monthly updates from PR
allow updated status for persons





Date of death Yes Yes (from SO) Yes Yes (both from PR and from the
Cause of Death Registry at National
Health Institute)
Yes
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Variable Denmark Finland Iceland Norway Sweden
Underlying cause
of death
No (available from Death Cause
Registry at National Health Data
Authority).
Yes (from SO) Yes (but only for those
who die from cancer)
Yes (from the Cause of Death
Registry)
Yes (from the Swedish
Cause of Death Register at




No (available from DCR and
Pathology Registry at National
Health Data Authority)
Yes (from SO) Yes (from 2003)
but only if the cause is
cancer
Yes (from the Cause of Death
Registry)
No (available from the
cause of death registry at
the National Board of
Health and Welfare)
Autopsy Included in macro
verification variable
Yes Yes Yes for medical autopsies,




SO: Statistical Office (Statistics Denmark/Finland/Iceland/Norway/Sweden)
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Web Table 5. Variables related to each cancer registered by the Nordic cancer registries.
Yellow background: This information is not directly available (in a qualitatively accurate manner) but may be derived with a modest extra effort.
Variable Denmark Finland Iceland Norway Sweden







1943-1977: ICD-7, modified. 1978 -
2003; ICD-O-3, based on conversion
of ICD-O-1 and ICD-O-2. From
2004; ICD-O-3
ICD-O-3 (for most cancers
diagnosed before 2007 the
ICD-O-3 code was translated
from ICD-7 via a conversion
matrix; translated codes do not
always offer as detailed cancer
categories as the ICD-O-3
nomenclature would allow)
1955-1979: ICD-7; 1980 -
1982: ICD-9; 1983- 1989:
ICD-O-1; 1990-2002:
ICD-O-2; 2003+: ICD-O-3.
All codes have been




(In addition localization of ICD7:
More detailed site of the neoplasm,
e.g.. extralymphatic localization,
extragonadal germ cell tumours
1958+: ICD7, 1987+: ICD9,





1978 - 2003; ICD-O-3,
based on conversion of
ICD-O-1 and ICD-O-2.
2004+; ICD-O-3
ICD-O-3 (plus some newer
ICD-O codes not in ICD-O-3 and
previously some self-made
additional codes for registered
disease entities that are not in
ICD-O-3). For most cancers
diagnosed before 2007 the
ICD-O-3 code was translated
from MOTNAC via a conversion
matrix; translated codes do not
always offer as detailed cancer
categories as the ICD-O-3
nomenclature would allow.
1955-1979: ICD-7; 1980 -
1982: ICD-9; 1983- 1989:
ICD-O-1; 1990-2002:
ICD-O-2; 2003+: ICD-O-3.
All codes have been
converted to ICD-10 for
purposes of reporting
and communication.
ICD-0-3 (plus some additional
self-made codes)
1958+: C24.1*, 1993+: ICD-O-2,
2005+:ICD-O-3










potential); 2 Carcinoma in situ
(Intraepithelial; Noninfiltrating;
Noninvasive); 3 Malignant




















3 Malignant, primary site
0' Benign; '1' Semimalignant (Borderline
malignancy, Low malignant potential,
Uncertain malignant potential); '2'
Carcinoma in situ (Intraepithelial;
Noninfiltrating; Noninvasive); '3' Malignant
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Variable Denmark Finland Iceland Norway Sweden
Method of
confirmation








Self-made codeN1  '5' Autopsy, microscopical; '3'Histology
from primary tumour; '5' Cytology; '8'
Laboratory finding; '7' Autopsy,
macroscopical; '6' Surgery; '2' X-Ray; '1'
Clinical;
Stage at diagnosis Before 2004, self-made
codes (localised, regional,
metastasis, unknown, Dukes).
2004+ TNM and Ann
Arbor
Self-made code:
0 Unknown; 1 Localized; 2
Metastases in regional lymph
nodes only; 3 Metastases
further than in regional lymph
nodes or tumour invades
adjacent tissues; 4 Non-
localized, unspecified. In 2012
two additions to the code: 5
Locally advanced, tumour
invades adjacent tissues; 6
Distant metastasis
No (see TNM↓) Self-made codeN2; detailed
UICC staging for breast cancer
(1953/1986 -->), cervical cancer
(1953/1991 -->), ovarian cancer
(2002 -->) and lymphomas
(1953/1993 -->)
No (see TNM↓)
TNM Since 2004 NoF1
(Since 2017 TNM is coded





UICC (AJCC) , 7th
edition, for following




years available for those
sites  along Thyroid.
Yes. Clinical TNM has been
registered when reported, but
information is incomplete.
Pathologic TNM is only registered
for the following cancer sites:
Rectal cancer: from 1993
Breast cancer: from 1986
Prostate cancer: from 2003
Colorectal cancer: from 2007




No (can be studied with linkage to
the National Patient Discharge
Registry, validity not perfect)
NoF1 (can be studied with
linkage to the national Care
Register, validity not perfect)




No (can be studied with linkage to
the national Patient Register).
Metastases with confirmed
histology are available.
Several quality registries now ask
for clinical information about
recurrence, but the completeness is
still not good.
No
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Variable Denmark Finland Iceland Norway Sweden
Treatment Available before 2004
(2004+ can be studied through
linkage to the National
Discharge Registry)
Treatment started





The completeness of this
information is so low and has
decreased over the years, i.e.,
it can only be utilised for








the first year after
diagnosis; self-made
codesN3
No (can be studied with linkage to the
national Patient Register)
Symptoms No No (Date of first symptoms
was asked in cancer
notification from the hospitals
but it was so incomplete that it
is has not been used lately. It is
possible to identify cancers
diagnosed in organised
screening via record linkage
with Mass Screening Registry.)
No Information was collected




For melanomas, symptoms are still
registered. There are also some
questions about "reason for
diagnostics" in some of the other
quality registries. This variable
might contain some information
about symptoms.
No
Other More detailed information
may be available from the





(died of this cancer;














Oesophagus and stomach 2015+
More detailed information
available from >25 clinical INCA
registries (Web Table 7)
Specifications:
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Variable Denmark Finland Iceland Norway Sweden
F1 More detailed information can be derived from the database which includes all information received on the cancer notifications (mainly free text).
F2 Finland - coding of treatment (incomplete data; can be better studied with linkage to the National Care Register)
Surgical treatment
                       0 no treatment
                       1, 4, 7 Radical
                       2, 5, 8 Palliative
                       3, 6, A Not known whether radical or palliative
                       9 Not known whether treated
                     NB: Codes 1, 2, 3 indicate treatment within 4 months of diagnosis. Codes 4, 5, 6 indicate treatment starting more than 4 months after diagnosis. Codes 7, 8, A
indicate that we do not know when the treatment started.
Radiotherapy
                       Codes as for surgical treatment
Cytostatic drug treatment
                       0 no treatment
                       1 treatment within 4 months of diagnosis
                       4 treatment starting more than 4 months
                         after diagnosis
                       7 not known when treatment started
                       9 not known whether treated
Hormone treatment
                       Codes as for cytostatic drug treatment
Other treatment
                       Codes as for cytostatic drug treatment
FI3 Finland, method of confirmation from 2017 onwards
7 Histological examination from primary tumour
8 Histological examination from autopsy specimens
6 Histological examination of metastasis
5 Cytological
4 Specific tumour markers
2 Clinical, including imaging diagnostics
1 Clinical
0 Death certificate only
9 Unknown
10 Flow cytometry
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Variable Denmark Finland Iceland Norway Sweden
12 Moleculargenetic analysis
13 Immunophenotyping
For cancers coded before 2017, selected in order of following reliability:
4 Histology from primary tumour
5 Autopsy, microscopical








Before 2014 histology from autopsy was considered as most reliable method.
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N1 Norway - Method of confirmation
00 Clinical examination without additional examinations outside a hospital
10 Clinical examination without additional examinations in a hospital
20 Imaging diagnostics (x-ray, Ultrasound, CT, MR)
22 Clinical notification about cytological examination
29 PSA test
30 Biochemical examination, electrophoresis
31 Endoscopic examination
32 Cytological examination of primary tumour
33 Blood smear
34 Bone marrow smear
35 Examination of spinal fluid
36 Cytological examination of metastasis
37 Cytological examination of local recurrence
38 Cytological examination with immunephenotyping, cytogenetics etc.
39 Cytological examination, uncertain if taken from primary tumour or metastasis
40 Surgical intervention without morphological examination
41 Autopsy without histological examination
46 Hormone receptor analysis
47 Moleculargenetic analysis, PCR
57 Histological examination of local recurrence
60 Histological examination of metastasis
(68) Not coded - Histological examination of metastasis AND autopsy. Automatically given from a combination of basis 60 and 80/82
70 Histological examination of primary tumour
(71) Not coded - Automatically given from a combination of DS 5 and Basis 32, 33, 34, 35, 39, 70, 74, 75, 76
72 Clinical notification about histological examination
74 Histological examination with electron microscope (ultrastructural diagnostics)
75 Histological examination with immunephenotyping, flow-cytometri
76 Histological examination with cytogenetics, moleculargenetic examination
(78) Not coded - Histological examination of primary tumour AND autopsy. Automatically given from a combination of basis 70 and 68/80/82.
79 Histological examination, uncertain if taken from primary tumour or metastasis
80 Autopsy with histological examination
81 Casual finding at autopsy with histological examination
82 Partial autopsy
83 Clinical notification about autopsy
98 Biopsy without any tumour
90 Death certificate
99 Unknown basis of diagnostics
Increasing priority: 71, 47, 46, 45, 99, 98, 90, 00, 10, 20, 30, 29, 31, 40, 83, 41, 82, 80, 22, 36, 39, 37, 32, 38, 72, 60, 79, 57, 70, 68, 78, 74, 75, 76, 81.
N2 Norway - Stage at diagnosis
0 No metastasis
1 or A Metastasis to regional lymph nodes
2 or B Metastasis to distant lymph nodes
3 or B Metastasis to organ in the same part of the body as the primary tumour
4 or B Metastasis to organ in another part of the body than the primary tumour
5 or D Microscopic growth into neighbouring tissue
6 or D Macroscopic growth into neighbouring tissue
7 Metastasis found, but uncertain where primary tumour is located
8 or D Microscopically infiltrating tumour
9 Unknown metastasis
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Childhood cancer 1985 2013 Collecting additional clinical data
Prostate cancer 2004 2009 Collecting additional clinical data (from 2004) andpathology data (from 2009)
Colorectal cancer 2007 2009 Collecting additional clinical and pathology data
Skin melanoma 2008 2013 Collecting additional clinical and pathology data
Breast cancer 2009 2013 Collecting additional clinical and pathology data
Lymphomas and lymphoid
leukaemias 2011 2013 Collecting additional clinical data
Ovarian cancer* 2012 2013 Collecting additional clinical and pathology data
Lung cancer 2013 2013 Collecting additional clinical and pathology data
Oesophagus and stomach
cancer 2015 ** Collecting additional clinical data
Planned
Haematological cancer ** Additional parameters for clinical and pathologydata established – not collecting data yet
Central nervous system
cancer **
Additional parameters for clinical and pathology
data established – not collecting data yet
Testicular cancer ** Additional parameters for clinical and pathologydata established – not collecting data yet
Sarcoma ** Additional parameters for clinical and pathologydata established – not collecting data yet
Bladder and urinary tract
cancer *** Planning additional parameters
* Will be extended to include all gynaecological cancers. Cervix uteri is the first additional site, hopefully in 2018.
** Applied for national funding, but the establishment of new quality registries is currently stopped in order to
evaluate the existing registries and discuss a better model of funding.
*** Not yet applied for funding.
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Web Table 7. Swedish Clinical Cancer Registries with national coverage on information network for
cancer (INCA) platform (April 2017).
1 National responsibilities for coordination (general support, update, statistical output) of registers are shared between
Regional Cancer Centres.
2 Part of the clinical cancer register of Gynecological Oncology.
3 From 2008 part of the clinical cancer register for head and neck cancer.
4 Different set of variables for acute lymphatic and acute myeloid/unknown leukaemia.
Cancer site National registration Coordinating Cancer Centre1
From On INCA platform from
Breast 2008 2008 Stockholm Gotland
Cervix/vagina2 2011 2011 West
Endometrium2 2010 2010 West
Central nervous system 1999 2009 North
Head and neck3 2008 2008 North
Pituitary gland 1991 2012 Stockholm Gotland
Colon 2007 2008 North
Leukaemia, acute4 2007 2007 South
Leukaemia, chronic lymphatic 2000 2007 Stockholm Gotland
Leukaemia, chronic myeloid 2002 2007 Uppsala Örebro
Lung 2008 2008 Uppsala Örebro
Liver/gallbladder 2008 2008 West
Lymphoma 2000 2007 South
Melanoma of the skin 2003 2009 South East
Multiple myeloma 2008 2008 West
Myelodysplastic neoplasms 2009 2009 Uppsala Örebro
Myeloproliferative neoplasms 2008 2008 Stockholm Gotland
Kidney 2005 2009 Stockholm Gotland
Oesophagus/stomach 2006 2007 North
Ovary2 2007 2008 West
Pancreas 2010 2010 South East
Penis 2000 2009 Uppsala Örebro
Prostate 1998 2007 Uppsala Örebro
Rectum 1995 2007 North
Testis 2009 2009 South
Thyroid 2013 2013 West
Urinary bladder 1997 2008 South
Vulva 2012 2012 West
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Figure 1. Time trends of incidence of leukaemia in men in four Nordic countries. Five-year
floating averages of age-standardised rates (World) 1943-2104. In 1978, 18% of leukaemia cases
were missing from the Swedish Cancer Registry (Mattsson 1984); the proportion now may be 
smaller.
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Figure 2. Incidence of pancreatic cancer in men in in the Nordic countries in 2009-2013, by age.
The proportion of malignancies detected via the Cause of Death Register is particularly high for
cancers not diagnosed or treated in hospital, e.g., cancers with a poor prognosis in the elderly
such as pancreatic cancer.
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Figure 3. Time trends of incidence of non-melanoma skin cancer in men in the Nordic countries
as reported by NORDCAN. Age-standardised rates (World) 1943-2014. Before 1978, Danish
Cancer Registry could not separate basal cell carcinoma from the other non-melanoma skin
cancers.
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Figure 4. Time trends of incidence of bladder cancer in men in the Nordic countries. Five-year floating
averages of age-standardised rates (World) 1943-2014. Part of the differences is explained by
registration: Denmark has more often than the others included urothelial tumours of grades 1-4,
unknown grade and “papilloma” in the bladder in the incidence.
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Figure 5. Time trends of incidence of prostate cancer in the Nordic countries. Age-standardised
rates (World) 1943-2014. There was a steep increase in the incidence after global introduction of
the PSA screening test in the early 1990s in all Nordic countries but in Denmark. In Denmark, the
increase in incidence after 2004 partly reflects inclusion of pathology register information.
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Figure 6. Geographical variation of incidence of thyroid cancer among women in the Nordic countries
in 2004-2010 (Patama & Pukkala 2016). The red area in mid Finland is consequence of excessive
testing with ultrasound.
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Figure 7. Time trends of cervical cancer in the Nordic countries in the screened age categories
30-69 years. Truncated age-standardised rates (World) 1943-2014. The downward trend in
incidence started at different times depending on the start of national organised cervical cancer
screening program.
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Figure 8. Time trends of female breast cancer in age 50-59 years in four Nordic countries.
Truncated age-standardised rates (World) 1943-2014. Start of countrywide organised
mammography screening varied from 1986 (Finland) to 2007-9 (Denmark); this caused major
increases in the incidence rates of the screened age category.
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Figure 9. Time trends of incidence of basal cell carcinoma (BCC) among men in the Nordic
countries in 1953-2015. Age-standardised rates (World), only the first BCC counted for each
person. Registration practices of BCC – which has normally not been counted as true cancer in
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